Category: BIND

In short: Hydroxyzine and promethazine are sedating antihistamines that are sometimes prescribed off-label as comfort medications during a benzodiazepine taper or Benzodiazepine-Induced Neurological Dysfunction (BIND), and neither one is reliably effective or universally safer than the other. Hydroxyzine has the narrower profile, but its label warns of a dangerous heart-rhythm problem; promethazine reaches more systems, including nausea, but its dopamine blockade can produce the very restlessness and movement symptoms, such as akathisia, that many patients already have. Both add to the sedation of a benzodiazepine, so whether to try either one is a decision made with the prescriber who knows the taper. At most they are adjuncts, and neither can replace a slow, carefully paced taper.

When patients move through a benzodiazepine taper or live with Benzodiazepine-Induced Neurological Dysfunction (BIND), the search for symptom relief turns up two medications more often than most others: hydroxyzine and promethazine. Both are sedating antihistamines that are sometimes prescribed off-label as comfort medications during withdrawal. Each one can help, and each one can disappoint. The question patients keep asking is which one is the better choice, and which one is safer.

Neither one is reliably effective for BIND or benzodiazepine withdrawal symptoms, and neither one is universally safer than the other. The right choice for an individual patient depends on which symptoms are most disruptive, what other medications are already in the picture, and how the nervous system is currently behaving. People respond to one, the other, both, or neither. Understanding the difference between these two medications helps patients and their prescribers make a more informed choice rather than treating them as interchangeable.

How These Two Medications Differ

Hydroxyzine is a first-generation antihistamine that crosses the blood-brain barrier and produces sedation, anxiolysis, and a mild calming effect on the autonomic nervous system. It does not act on benzodiazepine receptors, which is part of why it is sometimes considered useful during tapering. Patients who are reducing their benzodiazepine dose are often steered toward hydroxyzine because it does not reinforce the same receptor pathway they are trying to step away from.

Promethazine is also a first-generation antihistamine, but it sits in a different chemical family. Beyond histamine blockade, promethazine has anticholinergic activity, antiemetic properties, and weak dopamine antagonism similar to a low-potency antipsychotic. This broader pharmacological footprint is why promethazine is often used for nausea, motion sickness, and as an adjunct in pain control. The same broader footprint also means it can produce effects that hydroxyzine does not.

For BIND patients, this difference matters. BIND involves a complex set of symptoms that are not just about anxiety or sleep. Patients describe nausea, gastrointestinal disruption, akathisia, sensory sensitivity, and autonomic instability. A medication that addresses only the histamine system behaves differently from one that touches several systems at once, and the broader footprint brings cautions of its own, described below.

When Hydroxyzine Tends to Help

Some patients find hydroxyzine eases worry and helps with falling asleep; others notice little change. Patients describe a softening of generalized worry, an easier transition into sleep, and less reactivity to small triggers. The effect is usually moderate, not dramatic. Some patients use it as needed during difficult days. Others use it on a scheduled basis through the most active phase of a taper.

What Promethazine’s Label Covers

Promethazine’s label covers nausea and vomiting, motion sickness, and sedation rather than anxiety, which is where the two medications part ways. Whether it helps a given person is not something anyone can promise in advance. Physical restlessness during a taper can be akathisia, and a dopamine-blocking drug such as promethazine can make akathisia worse, so bodily agitation is a reason for caution with promethazine rather than a reason to reach for it.

Sleep is a similar story. Some people find that one of them helps and others find that neither does, and there is no reliable way to predict that in advance, which is one more reason the choice belongs in a conversation with the prescriber rather than in a ranking.

When Neither One Reaches the Suffering

A subset of patients will find that neither medication produces a meaningful effect. This is one of the difficult realities of advanced benzodiazepine withdrawal and BIND. The nervous system can become so dysregulated that a single off-label antihistamine is not strong enough to reach what is happening underneath. Patients in this position sometimes assume they have failed the medication, when in fact the medication has been asked to do something it was never designed to do.

What is happening underneath is physical dependence on a prescribed benzodiazepine, and physical dependence is not addiction. It is a medical condition produced by the medication. While a taper is still under way, the symptoms answer to its pace far more than to any comfort medication, and after a taper ends, BIND can persist for a time and needs patience and a physician who knows it. Thoughts of harming yourself, a seizure, or a collapse are reasons to call 911, or 988 if the thoughts are of suicide, rather than to wait for the next cut.

Comfort medications are tools rather than solutions. They help when they help, and when they do not, the answer is rarely to push the dose higher or stack additional medications. The answer is usually to slow the taper, reduce the rate of cuts, and let the nervous system settle. Managing a taper when no comfort medication works is its own subject, and a common one.

Comparing the Pharmacological Profiles

The safety question between these two medications is less simple than a ranking. Both are widely prescribed, and both have long track records in clinical use. The pharmacological profiles diverge in ways that matter for benzodiazepine tapering patients specifically, and both labels carry cautions that a tapering patient should know about.

Hydroxyzine has the narrower footprint of the two. It works almost entirely through histamine blockade with a mild calming effect on serotonergic pathways. It does not block dopamine to any meaningful degree, so it carries far fewer of the movement-related concerns associated with antipsychotic-class medications, and it has fewer points of interaction with other medications a tapering patient may already be taking. For patients who are already sensitive to neurological inputs, this matters. That does not make it clean. The hydroxyzine label warns that QT prolongation and torsades de pointes, a dangerous heart rhythm, have been reported, that the drug is contraindicated in patients with a known prolonged QT interval, and that caution is needed in patients with heart disease, electrolyte imbalance, or other medications that affect heart rhythm. Palpitations are common in BIND, and a patient who already has them should not assume the milder antihistamine is free of cardiac concern.

Promethazine carries a more complicated profile. The dopamine blockade is mild but real, and it puts the medication in the same pharmacological family as low-potency antipsychotics. Its label lists extrapyramidal symptoms, tremor, and the rare but serious neuroleptic malignant syndrome. The label also warns that promethazine may lower the seizure threshold, which matters for anyone in benzodiazepine withdrawal, since cutting too fast or stopping suddenly can itself bring on seizures. Akathisia, the inner motor restlessness that many BIND patients already know well, is a recognized effect of dopamine-blocking drugs as a class, even though the promethazine label does not name it directly. For a patient whose primary complaint already involves involuntary movement, motor restlessness, or akathisia, this is the wrong tool, because it can produce the very symptom it is being asked to relieve. Promethazine also has higher anticholinergic activity, which can be a concern in older patients or in patients already taking medications with anticholinergic load. Its label does not carry a heart-rhythm warning of the kind found on hydroxyzine’s label. The cardiovascular effects it lists are increased or decreased blood pressure, a fast or slow heart rate, and faintness. Even so, in a patient who already has palpitations, promethazine deserves the same care as hydroxyzine. That is ordinary prudence rather than a label requirement.

Both labels also warn about additive sedation when either drug is combined with other central nervous system depressants, and promethazine’s label adds the risk of slowed breathing. A benzodiazepine is a central nervous system depressant, and a tapering patient is by definition still taking one. That is an argument for the lowest useful dose and for the prescriber knowing exactly what else is on the list, not an argument against ever using them. Palpitations, fainting, or new chest pain on either medication are reasons to get checked promptly rather than to wait for the next cut. New chest pain or a collapse is a reason to call emergency services.

Hydroxyzine is indicated for anxiety and can help during a benzodiazepine taper, with the heart screening above in force. Promethazine’s broader footprint is the reason for the cautions above, and whether it belongs in a plan at all is a question for the prescriber. Either way, the choice is made with the prescriber who knows your taper, your heart history, and your other medications, and it is revisited if it does not help.

The Bigger Picture

Choosing between hydroxyzine and promethazine is rarely a simple question of which medication is better. It is a question of which symptom mix is in front of you, which other medications are in the picture, and how the nervous system has been behaving in recent weeks. Hydroxyzine is indicated for anxiety and can help during a benzodiazepine taper. For a patient with akathisia or motor sensitivity, hydroxyzine carries less movement-related risk than promethazine, though its label does report rare involuntary movements, tremor and convulsions, mostly at doses well above the recommended range, and the heart-rhythm caution above still applies. When the trouble is a racing heart, tremor, or blood pressure swings rather than nausea or sleep, other options are usually in the conversation with the prescriber.

What both medications share is that they are adjuncts. They support a careful taper, and they cannot replace one. The patients who do best are usually not the ones who find the perfect comfort medication but the ones whose tapering plan respects the pace their nervous system can handle. Comfort medications are one piece of a much larger picture, and the larger picture is the taper itself.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Patients with benzodiazepine-induced neurological dysfunction (BIND) and patients with mast cell activation syndrome (MCAS) frequently describe overlapping symptoms: flushing, gastrointestinal (GI) trouble, palpitations, sensory hypersensitivity, new food and medication reactions, sleep disruption, and an episodic course. The overlap is striking enough that patients in either community often meet criteria for the other, and clinicians familiar with both conditions routinely see the same patient carry both labels, sometimes with both diagnoses independently warranted, sometimes with one being the misidentified expression of the other. If you carry both labels yourself, or suspect you should, this article is about how to think that through.

Whether MCAS in this population represents an independent condition, a reactivation of latent mast cell instability, or the inflammatory-autonomic component of BIND itself is unresolved. The diagnostic stakes are real: the two conditions share some management principles but differ in others, and the MCAS workup has specific requirements that a general workup does not produce.

What mast cell activation syndrome is.

Mast cell activation syndrome is a diagnosis with competing definitions. The stricter definitions require three features: episodic symptoms involving at least two organ systems consistent with mast cell mediator release; objective evidence of mediator release (a rise in serum tryptase above baseline during an episode, or elevated 24-hour urine histamine metabolites, prostaglandin D2 metabolites, or leukotriene E4); and response to mast cell-directed therapy.

Looser definitions accept the clinical presentation and response to treatment with less stringent laboratory confirmation. The difference matters because the looser definitions capture a much larger patient population, and there is genuine debate about how much of that population has mast-cell-driven disease versus other mechanisms producing similar symptoms.

Primary mastocytosis, a clonal mast cell disease, is a separate diagnostic category with bone marrow findings and, typically, elevated baseline tryptase. It is uncommon. MCAS as the term is used clinically today usually refers to non-clonal activation without the bone marrow findings of mastocytosis.

What BIND is.

BIND refers to the persistent neurological, cognitive, and autonomic symptoms that can follow prolonged benzodiazepine exposure. One theory is that durable changes in gamma-aminobutyric acid type A (GABA-A) receptor function are joined by secondary neuroinflammation, autonomic dysregulation, and changes in the hypothalamic-pituitary-adrenal (HPA) axis, the body’s stress-hormone system. Clinical features include sensory hypersensitivity, cognitive symptoms, autonomic instability, tremor, paresthesias (tingling or burning skin sensations), mood changes, and GI symptoms. Onset is typically during or after a benzodiazepine taper, sometimes months to years after discontinuation.

BIND follows physical dependence on a medication that was prescribed, and physical dependence is not addiction: it is a nervous system that adapted to a drug it was given and is now readjusting, slowly, after the drug is reduced or gone.

BIND is not a primarily immune syndrome in the current formulation, but the overlap with immune-inflammatory conditions draws attention. Microglia, the immune cells of the brain, are one proposed driver. Peripheral mast cells, which communicate with central structures through vascular and neural pathways, have been proposed as a contributor to the inflammatory signal in a subset of patients. All of this is theory rather than settled fact.

The overlap that produces the clinical question.

Several features recur in patients carrying both labels or in patients being evaluated for both.

New food and medication reactions come first. A patient who tolerated a broad diet and multiple medications before a taper develops intolerances during or after withdrawal. Some reactions look allergic (hives, flushing, gut symptoms); others look like sensitivity without the allergic features. The pattern is consistent with mast cell involvement, and it is also consistent with broader sensory-autonomic hypersensitization that does not require mast cell activation. These overlapping presentations are explored further in related discussions of new food sensitivities during a taper, histamine intolerance and the low-histamine diet, and allergy-like symptoms mistaken for new environmental allergies.

Episodic autonomic symptoms are the second shared feature. Tachycardia (a racing heart), flushing, and sweating in episodes lasting minutes to hours occur in both conditions. The pattern is shared even when the underlying driver differs.

Sensory and sleep symptoms overlap as well. Light and sound sensitivity, insomnia, and disrupted sleep are common in both populations.

GI symptoms are reported by both groups: bloating, cramping, altered bowel habits, and nausea. Mast cells are densely present in the gut, which supports a mast cell contribution when other evidence aligns.

Stress reactivity rounds out the list. Both conditions show symptom amplification with physical stress, infection, and psychological stress. The symptoms themselves do not distinguish them.

Possible explanations for the overlap.

Several explanations have been proposed, and more than one may be true at once. Each is one theory, not an established mechanism.

Unmasking of pre-existing mast cell instability is the first. Some patients may have had subclinical mast cell activation before the benzodiazepine was started. Some laboratory work suggests benzodiazepines can quiet mast cells, which is one reason symptoms may surface when the drug is withdrawn.

Neuroimmune sensitization produced by withdrawal is the second. Chronic disruption of GABA signaling may alter microglial and mast cell behavior in ways that sensitize both to later triggers. The symptom picture then reflects a downstream immune-autonomic instability rather than an independently existing condition.

Shared upstream drivers are the third. Chronic stress, HPA axis alteration, and autonomic imbalance can drive mast cell activation through the sympathetic nervous system and other pathways. A patient in protracted autonomic dysregulation from withdrawal may develop mast cell features as a consequence rather than as an independent condition.

Separate coexisting diseases are the fourth. Some patients have genuine MCAS that would be symptomatic regardless of benzodiazepine exposure, and BIND in addition. The two conditions then add to each other.

No test currently sorts a given patient cleanly into one of these categories. Clinicians usually work with probabilities based on the symptom pattern and the response to whatever is tried.

When the MCAS workup is worth doing.

A targeted MCAS evaluation is reasonable when specific features are present beyond the general symptom overlap.

Objective episodic findings carry the most weight. Photographed flushing, documented low blood pressure during episodes, or hives that resolve between episodes all support mast cell involvement. Tryptase drawn during an active episode, along with 24-hour urine methylhistamine and prostaglandin D2 metabolites, provides the laboratory correlate.

Response to mast cell-directed therapy is a second signal. Some patients and their doctors try a course of a second-generation histamine type 1 (H1) blocker together with a histamine type 2 (H2) blocker and watch what happens to the episodes. The evidence for this as a diagnostic step is limited, and a response does not prove MCAS any more than a non-response rules it out. Whether to try it, which medications, and for how long are decisions to make with the prescriber who knows your taper, not something to start on your own mid-taper.

Family history is a third. A clustering of mast cell symptoms among relatives makes mast cell involvement more likely.

A trigger profile consistent with mast cell activation is the fourth. Reactions to temperature extremes, physical pressure on the skin (dermographism, where a firm scratch raises a welt), specific foods known to be histamine-rich, and certain pain and muscle medications are more suggestive of mast cell involvement than the general sensory hypersensitivity of BIND.

One caution belongs here. Some episodes are neither withdrawal nor routine MCAS: an episode with swelling of the lips, tongue or throat, trouble breathing, chest pain, or fainting is an emergency, and the right response is to call 911 rather than wait it out.

What a positive or negative workup changes.

If the workup is positive for MCAS, management adds a set of tools that some patients and their doctors try: H1 and H2 blockers, mast cell stabilizers (cromolyn and ketotifen are the usual examples), and avoidance of known triggers. Evidence in this population is limited, responses vary widely from one patient to the next, and what to try is an individualized decision with your prescriber.

If the workup is negative but the picture remains suggestive, some clinicians still try mast cell-directed treatment. The absence of objective laboratory findings does not fully exclude a contribution. This is pragmatic management in a syndrome where the underlying question is not fully answerable, and it works best when patient and prescriber agree in advance on what a real response would look like.

Patients with BIND should be cautious with mast cell-directed medications that act on benzodiazepine receptors or have GABA-related effects. First-generation H1 blockers such as hydroxyzine and diphenhydramine have central nervous system effects that can muddy the BIND picture and are usually better avoided in favor of second-generation H1 agents. Many antihistamines, including some second-generation ones, carry a label warning that sedatives may increase drowsiness, which is another reason to talk it through with your prescriber first.

The BIND component requires the usual approach: hyperbolic tapering if you are still on a benzodiazepine, autonomic stabilization, paced activity, and time. Adding mast cell management does not substitute for this. Some patients find it makes the autonomic side of BIND more tolerable while the underlying syndrome resolves. Others notice no difference.

The question that matters in practice.

Whether MCAS in BIND patients represents a separate disease, a co-activated immune axis, or a renaming of the inflammatory-autonomic component of BIND itself is not fully resolved. Clinically, the distinction matters less than the practical question of whether you benefit from mast cell-directed treatment in addition to BIND management. For patients with the features above, it is often worth a careful trial with the prescriber. For patients without those features, mast cell-directed treatment is unlikely to change the course, and the effort is better spent on the BIND itself: the taper, the pacing, and the time the nervous system needs to heal.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Why does food just sit there during a benzodiazepine taper?

Why would a stomach stop emptying in the middle of a benzodiazepine taper? Is it the withdrawal, or a new disease with bad timing? For a minority of people in withdrawal, and for some living with benzodiazepine-induced neurological dysfunction, or BIND, the lasting injury long benzodiazepine use can leave on the nervous system, it starts with fullness after a few bites, nausea that lingers after meals, a tight, bloated upper belly, and weight loss without trying.

The medical name for a stomach that empties too slowly with no blockage to explain it is gastroparesis, and a workup in this group often ends with “idiopathic,” meaning no cause found.

The Ashton Manual does not use the word, but it describes the neighborhood. Chapter 3, Table 1 lists nausea, vomiting, pain, and distension among the gastrointestinal symptoms of withdrawal, and the chapter notes that considerable weight loss sometimes occurs. So, a stomach misbehaving in withdrawal is nothing new. The question is why it would slow to a crawl.

One theory ties it to the vagus nerve and the rest of the autonomic picture.

Your stomach takes its cues from the autonomic nervous system, which runs heart rate, blood pressure, temperature, and digestion without asking you, and the cue for digestion travels mainly along the vagus nerve, the main nerve of the “rest and digest” branch. When the vagus speaks clearly, the stomach relaxes to make room, grinds and pushes, and opens its outlet on time.

Benzodiazepines strengthen the brain’s main calming messenger, gamma-aminobutyric acid, or GABA, and over years the brain scales back its own calming machinery. During a taper the borrowed calm leaves faster than the brain can rebuild its own, and the body ends up in the overdriven state described in A Nervous System Without Brakes. The Ashton Manual, in Chapter 3, calls the pounding heart and sweating of withdrawal “simply the expression of an overactive autonomic nervous system.”

The vagus theory takes one more step. If the sympathetic, fight-or-flight side is stuck on, the calming side, which includes the vagus, is likely under-powered too, and a stomach that depends on it would slow for the same reason the heart speeds up. That hypothesis fits the pattern, but no source this publication cites has established that vagal tone is measurably reduced in this group.

A homely comparison may help. While this is not a perfect analogy, a stomach with a muddled vagal signal is like a checkout conveyor belt with a faulty pedal: it runs in fits and starts, groceries pile up, and the sensible answer, until the pedal is fixed, is to put less on the belt at a time.

How can you tell whether the slow stomach belongs to the withdrawal?

No test proves that a slow stomach is withdrawal-related, but the pattern usually tells. The first clue is timing: symptoms that arrived during a taper or after the last dose, not years before the prescription.

The second clue is company. A stomach that slows alongside a racing heart, temperature swings, dizziness on standing, and bladder changes belongs to a family of autonomic symptoms, while gastroparesis arriving alone is more suspicious of a separate cause. Slow emptying often sits inside the wider gut picture described in Benzo Belly Is Real.

The third clue is rhythm. In fact, the Ashton Manual notes in Chapter 3 that withdrawal symptoms “characteristically wax and wane, varying in severity and type from day to day, week to week,” and a withdrawal-related stomach keeps that rhythm, worsening after a cut and easing during a hold. By contrast, a stomach disease of its own does not care what your dose did last Tuesday.

Some causes are not withdrawal, and those need to be checked.

Other conditions slow the stomach and deserve their own treatment: diabetes, an underactive thyroid, past stomach surgery, some autoimmune conditions, and medications including drying, anticholinergic drugs and the newer injectable diabetes and weight-loss medicines.

Certain features need prompt evaluation whatever you are tapering: weight loss that keeps going, vomiting that will not stop, blood in vomit or black stools, severe or worsening abdominal pain, fever, trouble swallowing, or new thirst with frequent urination. If you cannot keep fluids down, faint, vomit blood, or have chest pain, go to the emergency room or call 911. Nothing about a taper makes emergency care the wrong choice.

Either way, confirmation and exclusion belong with a gastroenterologist, who can measure how quickly your stomach empties, rule out a blockage, and check the causes above. Bring a written taper timeline, and ask that it be part of the picture rather than filed under anxiety.

What can you do that carries no risk?

Here the conveyor belt earns its keep. Small, frequent meals ask less of a slow stomach, and softer, lower-fat food moves through more easily than a large, rich plate, with liquids on the worst days. Staying upright for an hour after eating lets gravity help, and a short walk after a meal beats lying down.

Hydration matters twice over, because dehydration worsens the dizziness on standing that often travels with this picture, and small sips through the day sit better than large drinks. A simple log of meals, flares, and dose changes soon tells you more than any general rule.

While many patients try ginger tea, peppermint, or slow breathing before meals, no claim is made here about what those do. Some find them settling and others notice nothing, so one change at a time, with your doctor in the loop, is the rule for a nervous system that can react to anything new.

Why is metoclopramide often a poor fit for a sensitized nervous system?

Reglan, or metoclopramide, is the prokinetic most doctors reach for, and the one with an approval in the United States, which the label limits to diabetic gastroparesis. It blocks dopamine receptors and crosses into the brain, and its label says that restlessness, drowsiness, and fatigue occur in roughly one patient in ten, and that it can cause akathisia, described there as anxiety, agitation, jitteriness, insomnia, and an inability to sit still.

Many people in a taper are already fighting exactly those symptoms. In Dr. Leeds’ experience, which varies from clinician to clinician and patient to patient, people with BIND or protracted withdrawal often tolerate metoclopramide poorly.

Metoclopramide also has a boxed warning for tardive dyskinesia, a potentially irreversible movement disorder, and the label says to avoid more than 12 weeks of total treatment, so it was never meant to carry anyone through a long taper. It warns as well that combining it with sedatives, hypnotics, or anxiolytics raises the risk of central nervous system depression, and a benzodiazepine is all three.

The label further notes that depression, including suicidal thoughts, has occurred in people taking it. If you ever have thoughts of harming yourself, on this medicine or off it, call or text 988, the Suicide and Crisis Lifeline, or go to the nearest emergency room.

Yet, none of this is a ban. Some patients use a short course under supervision and do fine, and the decision belongs with you and your doctors, label in hand.

Slowing the taper often relieves the flare.

Unfortunately, much of medicine treats the stomach as one problem and the taper as another. When slow emptying flares after a cut, the most reliable relief many patients describe is a pause in the reductions. The Ashton Manual, in Chapter 2, says you can “stand still at a certain stage in your schedule and have a vacation from further withdrawal for a few weeks,” while trying “to avoid ever increasing the dosage again.”

A hold is not a failure. The 2020 benzodiazepine label update from the Food and Drug Administration, or United States Food and Drug Administration (FDA), says that no standard tapering schedule suits every patient, and that stopping abruptly or reducing too quickly can cause withdrawal reactions, including seizures, which can be life-threatening. A seizure at any point in a taper is an emergency, and a stalled stomach is a reason to slow down, never a reason to stop the medication or to be rushed off it.

That rushing usually comes from a misunderstanding. Physical dependence is not addiction. A body that adapted to a prescribed medication over years needs time to adapt back, and the treatment is a taper slow enough for the body to keep up, with holds when it cannot. Tell your prescriber when the stomach flares after a cut, since a taper is a negotiation between two people who both want it to end well.

Slow emptying tends to settle as the nervous system does.

Withdrawal-related gastroparesis behaves like the rest of BIND: it waxes and wanes, it responds to holds, and in clinical experience it tends to improve as the taper ends and the months pass. Dr. Leeds’ view is that treating it as one expression of a system slowly rebalancing leads to more patient and better care than treating it as a diagnosis standing alone.

Fortunately, the practical side does not depend on whether the vagus turns out to be the missing link. What clinical experience does support is that a stomach which slowed with the taper usually speeds back up as the nervous system settles, and yours, given time and a taper it can keep up with, has a good chance of finding its rhythm again.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

If you are in protracted benzodiazepine withdrawal, there is a fair chance a Lyme disease workup has come up somewhere along your diagnostic odyssey. The reasons are understandable. The symptom overlap is real: fatigue, cognitive dysfunction, paresthesias, autonomic instability, muscle and joint pain, sleep disruption, and sensory hypersensitivity are common to both clinical pictures. You have been told your symptoms are not anxiety, imaging is normal, and the list of plausible alternative explanations is short. Lyme disease is on that short list, particularly in regions where tick-borne illness is common, and the workup gets ordered.

The clinical question is what that workup can meaningfully establish, and what should happen with the results. The answer is less straightforward than either side of the Lyme disease debate usually presents, and getting it right matters: the wrong conclusion can commit a withdrawal patient to months of antibiotic treatment that does not address the actual syndrome and can, in some cases, produce its own harms.

What is and is not settled about Lyme disease.

Three clinical entities frequently get grouped under “Lyme” and benefit from being kept separate.

Acute Lyme disease is an infection with _Borrelia burgdorferi_ (and related species) transmitted by Ixodes ticks. Diagnosis is based on the clinical picture, typically supported by serology (an enzyme-linked immunosorbent assay, or ELISA, followed by a Western blot) once the antibody response has developed. Early localized disease presents with erythema migrans in most cases and is treated with a course of doxycycline or amoxicillin. This part of the picture is not controversial.

Post-treatment Lyme disease syndrome (PTLDS) is a recognized entity in which a subset of patients treated for documented Lyme disease have persistent symptoms (fatigue, cognitive dysfunction, musculoskeletal pain) lasting six months or more after completion of standard antibiotic therapy. Whether PTLDS represents ongoing infection or a post-infectious process is not fully resolved, but the standard guidelines do not support prolonged antibiotic treatment as effective for it.

“Chronic Lyme disease” as used in some clinical settings refers to persistent symptoms attributed to _B. burgdorferi_ infection in patients who may or may not have serologic evidence of exposure and who may not have had documented acute infection. This usage is contested. The standard guidelines do not recognize it as a distinct infectious entity in patients whose blood tests are negative. Other clinical groups take a broader view.

The practical consequence for you as a patient in benzodiazepine withdrawal is that the label “Lyme” can mean very different things depending on who applies it and on the workup findings.

The symptom overlap in detail.

Several symptom clusters recur in both protracted benzodiazepine withdrawal and post-treatment Lyme disease syndrome, and you may recognize most of them.

Cognitive dysfunction comes first: attention and concentration difficulties, word-finding problems, and slowed processing speed are common to both. Musculoskeletal symptoms follow: joint pain, muscle aches, and migratory discomfort are reported in both, though the arthritic pattern of Lyme disease (large-joint, often a single joint, with documented swelling) is more specific when present. Profound fatigue, often with post-exertional worsening, characterizes both.

Autonomic features such as palpitations, orthostatic intolerance, temperature dysregulation, and gastrointestinal (GI) symptoms appear in both. So do neurologic sensations (paresthesias, tremor, muscle twitches, and sensory hypersensitivity) and sleep disruption, with difficulty initiating or maintaining sleep and a non-restorative quality.

The overlap is wide enough that symptom profiles alone do not distinguish the two. Additional data (exposure history, serology, pattern over time) are what allow any useful separation.

When a Lyme workup is genuinely indicated.

If you are in protracted benzodiazepine withdrawal, several features make a tick-borne illness more likely and make a serologic workup clinically reasonable.

The first is known tick exposure: a documented tick bite, particularly in an endemic region and particularly if the tick was attached for a day and a half or longer. The second is a history of erythema migrans. Even a remote history of a bull’s-eye rash or a characteristic expanding red patch makes Lyme considerably more likely. The third is characteristic early features in the history: facial palsy, heart block, or large-joint arthritis that is not otherwise explained and was not previously attributed to Lyme.

The fourth is progressive neurologic findings. Lyme neuroborreliosis can produce radiculopathy, meningitis, and encephalomyelitis, each with specific examination and cerebrospinal fluid (CSF) findings that would not be expected in benzodiazepine withdrawal. The fifth is geographic context: residence in or travel to areas with high Ixodes density.

Some of these features are red flags in their own right. A seizure, chest pain, a fainting spell or a very slow pulse, sudden loss of vision or hearing, or a stiff neck with fever is not something to wait out as a wave. Call emergency services. A new facial droop needs to be seen the same day.

Patients without any of these features, whose symptom picture is entirely consistent with protracted withdrawal, are not well served by a Lyme workup as the first diagnostic step. The chance of Lyme is low to begin with, and positive results become difficult to interpret.

The serology and its limitations.

Two-tier testing (ELISA followed by Western blot if the ELISA is positive or equivocal) is the standard approach. The test has real limitations, and it helps to know them before you see a result.

False negatives occur in early infection, before the antibody response develops. This is less relevant in a chronic symptom picture than in acute evaluation. False positives occur with some cross-reacting infections and some autoimmune conditions.

Seropositivity in an endemic region does not establish that current symptoms are due to Lyme. A patient with remote exposure can have residual antibodies that persist for years or decades without current active infection. Interpreting seropositivity as proof of active chronic infection is where diagnostic reasoning frequently goes wrong.

Alternative testing is sometimes used by clinicians taking a broader “chronic Lyme” view: polymerase chain reaction (PCR) on serum, urine antigen tests, CD57 lymphocyte panels (a count of one subset of immune cells), and other tests outside the standard laboratory methods. These tests have variable supporting evidence and in several cases have not been validated to the standard required for clinical decision-making. A positive result on a non-standard test in a patient whose history does not otherwise support Lyme should be treated with considerable caution.

The risk of getting this wrong.

Three harms follow from misattributing a withdrawal syndrome to chronic Lyme.

Prolonged antibiotic treatment, commonly for months, is sometimes recommended under the chronic Lyme framework. This carries its own risks. Fluoroquinolones, in particular, are hazardous in patients with benzodiazepine-induced neurological dysfunction (BIND): the fluoroquinolone class can produce persistent neurologic and musculoskeletal effects of its own, and in a nervous system already destabilized the risk is substantial. Professor Ashton’s 2011 supplement to the Ashton Manual is explicit that quinolone antibiotics displace benzodiazepines from their binding sites and should not be taken by patients on, or recently on, benzodiazepines. Prolonged tetracyclines and macrolides affect the gut microbiome and have their own side effect profiles. Intravenous antibiotic regimens add line-related risks.

The underlying withdrawal syndrome is not addressed. Months spent on an antibiotic regimen for a condition that is actually protracted withdrawal is time during which your actual healing from withdrawal is not being supported and during which additional pharmacologic insults are being added.

Patient resources are consumed. Chronic Lyme treatment is often paid out of pocket, and the burden falls on a patient population that has usually already spent substantial resources on the workup to date.

A reasonable approach.

If you are in protracted benzodiazepine withdrawal and considering whether to pursue a Lyme workup, a pragmatic sequence works better than either reflexive ordering or reflexive dismissal.

Review the actual exposure history and clinical features with your doctor. If any of the supporting features listed above are present, proceed with standard two-tier serology.

Interpret positive serology carefully. A positive Western blot in a patient with a compatible history warrants infectious disease consultation. A positive result without supporting clinical features raises the question of remote exposure rather than active chronic infection.

Be cautious with non-standard testing and with clinicians whose framework does not engage with the standard guideline criteria. Your interest is in an accurate diagnosis, which is not served by a clinical setting that produces positive diagnoses as a default.

If Lyme is excluded or not supported, return to the withdrawal framework and manage accordingly. The symptoms that prompted the workup do not become less real because Lyme was not the cause. Physical dependence on a prescribed benzodiazepine is not addiction. It is a medical condition caused by the medication, and its symptoms continue to warrant the management appropriate to their actual origin.

What the clinical picture usually shows.

In clinical experience, most patients in protracted withdrawal who get Lyme workups have negative or non-diagnostic results, and their symptoms continue to track with the windows-and-waves pattern characteristic of protracted withdrawal rather than with the pattern expected for tick-borne illness. In a smaller group, serology is positive with features consistent with prior exposure, and the question becomes how much of the current picture is attributable to each condition, usually resolvable through response to treatment and the passage of time.

Lyme disease is worth considering when your clinical features warrant it, and not worth defaulting to when they do not. Over-attribution costs more than under-attribution when the baseline syndrome is a withdrawal picture that the history already explains.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

If you have been through a long benzodiazepine withdrawal and someone has suggested you might have chronic fatigue syndrome, or the reverse, you are not alone in that confusion. Patients with protracted benzodiazepine withdrawal and patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) present with remarkably similar clinical pictures: profound fatigue, cognitive dysfunction, unrefreshing sleep, orthostatic intolerance, and post-exertional worsening of symptoms. A patient in either category, if presented to a clinician unfamiliar with both, frequently gets assessed along whichever framework the clinician is more familiar with. Whether the two syndromes represent overlapping expressions of shared mechanisms or distinct conditions that happen to converge phenotypically is an open question, and one with meaningful implications for management.

Physical dependence on a prescribed benzodiazepine is not addiction. It is the expected result of regular use, and a slow taper exists to unwind it.

How ME/CFS Is Currently Defined

ME/CFS has been defined by several criteria sets over the past three decades, each drawing somewhat different boundaries around the condition. The current diagnostic criteria require a substantial reduction in the ability to engage in pre-illness activities lasting more than six months, accompanied by fatigue that is not substantially relieved by rest; post-exertional malaise (PEM), meaning a worsening of symptoms after physical, cognitive, or emotional exertion, often delayed by a day or more and out of proportion to the triggering activity; unrefreshing sleep; and at least one of cognitive impairment or orthostatic intolerance.

Post-exertional malaise is the defining feature and is what most distinguishes ME/CFS from conditions with superficially similar fatigue profiles.

Where Protracted Withdrawal and ME/CFS Overlap

The phenotypic overlap is substantial.

Fatigue. Both conditions produce fatigue that is disproportionate to activity, not relieved by rest, and substantial enough to restrict daily function.

Cognitive dysfunction. Attention and concentration problems, word-finding difficulty, slowed processing, and short-term memory difficulties occur in both.

Sleep dysfunction. Both populations describe non-restorative sleep, often with abnormal architecture, insomnia, and frequent awakenings.

Orthostatic intolerance. Postural tachycardia syndrome and other orthostatic patterns are common in ME/CFS and are also present in many patients with protracted benzodiazepine withdrawal as part of a broader autonomic dysregulation.

Sensory hypersensitivity. Intolerance to light, sound, and stimuli of all kinds appears in both.

Pain. Myalgia and widespread musculoskeletal pain occur in both.

Post-exertional worsening. This is where the frameworks begin to separate. Patients with protracted benzodiazepine withdrawal often describe worsening of symptoms after exertion, but the pattern is variable. Patients with ME/CFS classically describe a reproducible, delayed-onset deterioration that is severe and disabling out of proportion to the triggering activity, which is PEM in its classical form. Whether protracted withdrawal produces this same phenomenon or a less specific post-exertion flare pattern is not fully resolved. Clinically, some patients with protracted withdrawal appear to have genuine PEM that is indistinguishable from what patients with ME/CFS describe.

Shared Mechanistic Candidates

Several proposed mechanisms of ME/CFS have close analogues in the proposed mechanisms of protracted benzodiazepine withdrawal and benzodiazepine-induced neurological dysfunction (BIND). None of these is settled, and they are best read as hypotheses rather than findings.

Neuroinflammation and microglial activation. Activation of the brain’s resident immune cells has been proposed as a contributor in ME/CFS, and a similar process is suspected in benzodiazepine withdrawal.

Autonomic dysregulation. Sympathetic overactivity, parasympathetic dysfunction, and orthostatic patterns are reported in both.

Hypothalamic-pituitary-adrenal (HPA) axis alteration. Blunted cortisol response patterns are described in ME/CFS and suspected in protracted withdrawal.

Mitochondrial dysfunction. One line of thinking about ME/CFS centers on altered cellular energy metabolism. Whether the same applies in benzodiazepine withdrawal is unknown, though it is plausible.

Mast cell involvement. A subset of patients in each condition shows features compatible with mast cell activation.

The overlap of mechanistic candidates does not establish that the conditions are the same. It does suggest that a patient with features of both may be expressing a final common phenotype that multiple upstream insults can produce.

Where the Conditions Differ

Some features distinguish the two.

Triggering event. ME/CFS typically follows an identifiable trigger in most patients: a viral illness most commonly, an acute infection, physical trauma, or severe stress. Protracted withdrawal and BIND have a specific pharmacologic trigger: benzodiazepine exposure and discontinuation. A patient without such a history is not a BIND patient even if they have an ME/CFS-like picture.

Time course. ME/CFS tends toward a more stable baseline, with PEM as the main source of fluctuation. Protracted withdrawal classically shows a windows-and-waves pattern with gradual improvement over years. Both have variability, but the texture is usually somewhat different.

Response to removing the triggering variable. Withdrawal-related symptoms often improve over the months and years following benzodiazepine discontinuation. ME/CFS does not have an equivalent triggering variable to remove, and its natural history varies.

The same kind of sorting comes up with other conditions that resemble protracted withdrawal. The overlap with long COVID and the question of Lyme disease workups follow the same logic: the history, not the symptom list, tells the conditions apart.

What This Means for Management

Two management principles are shared across both conditions and are useful for any patient with substantial overlap.

Pacing, not graded exercise. Graded exercise therapy, once standard advice for ME/CFS, is now widely recognized as potentially harmful. The alternative is pacing: staying within an energy envelope that does not trigger post-exertional worsening, since pushing through symptoms tends to make them worse. The same approach serves patients with protracted withdrawal and PEM-type features.

Orthostatic support. Increased fluid and salt intake, compression garments, and position changes are useful in both populations. Pharmacologic options (fludrocortisone, midodrine, ivabradine for inappropriate tachycardia) have a role in selected patients; in benzodiazepine patients, the choice of agent should consider the additional medication burden and the specific side-effect profile.

Several differences in management apply when a patient is still on a benzodiazepine or actively in the protracted withdrawal phase.

Medications commonly used in ME/CFS that have benzodiazepine-like or GABAergic effects, such as clonazepam for sleep, gabapentin for pain, or pregabalin for autonomic features, should be approached with caution. They may provide symptomatic relief, but they add to the pharmacologic complexity of the underlying withdrawal picture, and each of them brings withdrawal symptoms of its own if stopped abruptly. The gabapentin and pregabalin labels also carry a shared caution: combined with other central nervous system depressants, benzodiazepines included, they add to sedation and to the risk of respiratory depression.

The taper itself, where still relevant, is the central management. A patient who is still on a benzodiazepine has a physical dependence, which is a medical condition caused by the medication and not an addiction, and the treatment that matches that condition is a gradual, patient-directed taper. A patient with ME/CFS-like features who is still on a benzodiazepine is typically better served by a careful taper than by a stepwise addition of ME/CFS-oriented medications.

What the Label Should Be

For a patient with a benzodiazepine exposure history and an ME/CFS-compatible clinical picture, three positions are defensible.

If the patient was well before benzodiazepine exposure, developed the syndrome during or after the taper, and has no ME/CFS trigger history, the working diagnosis is protracted withdrawal or BIND with an ME/CFS-like phenotype. Management follows the withdrawal framework first.

If the patient had ME/CFS before benzodiazepine exposure and the withdrawal has exacerbated it, both conditions are present. Management addresses both.

If the patient has a classical ME/CFS trigger (acute viral illness, for example) with no clear benzodiazepine contribution, the diagnosis is ME/CFS regardless of concurrent benzodiazepine use. The benzodiazepine may still warrant tapering, but that is a separate clinical question from the ME/CFS itself.

Whichever label fits, neither condition explains everything. Fever, marked or continuing weight loss, fainting with loss of consciousness, or a new neurological problem such as weakness on one side of the body should never simply be attributed to withdrawal or to ME/CFS; each needs its own workup. Sudden weakness, a collapse, or any symptom that is new and severe is a reason to call emergency services rather than wait it out.

The diagnostic question is worth addressing explicitly rather than collapsing into whichever label the first evaluating clinician applies. The two frameworks share enough that many interventions serve both; they differ enough that management needs to reflect which is driving the current picture. If you are the patient in this picture, the most useful thing you can bring to your physician is the history in order: what you were like before the benzodiazepine, what changed and when, and what has happened since the dose came down.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Can a benzodiazepine taper make your jaw clench and your neck pull?

Yes, and it does so often enough that Professor C. Heather Ashton wrote it into the Ashton Manual. Chapter III, in the section on muscle symptoms, describes benzodiazepines as efficient muscle relaxants whose withdrawal brings a rebound increase in muscle tension, with stiffness “affecting the limbs, back, neck and jaw.” The same chapter says pain in the jaw and teeth is probably due to involuntary clenching, much of it during sleep, and its Table 1 lists neck, teeth and jaw pain among the physical symptoms.

What usually happens instead is that the jaw gets treated as a jaw. A dentist or a specialist in temporomandibular disorder, or TMD, finds normal imaging, fits a bite splint, and sends you to physical therapy with an NSAID, a nonsteroidal anti-inflammatory drug such as ibuprofen. When none of that helps, the word “chronic” appears in the chart, or stress is blamed, and the taper that started the month the clenching began is never mentioned.

Yet, even when the two coexist, treating the joint alone leaves a driver in the nervous system untouched. So, how do you tell them apart, and what do you do when nobody has asked about your medication list?

Why does lowering the dose tighten the muscles?

Benzodiazepines amplify GABA, or gamma-aminobutyric acid, the nervous system’s main calming signal, and that is why they relax muscles as well as nerves. After months or years the nervous system adapts by turning its own calming machinery down. Yet, lower the dose and the adaptation is still there, so muscle tone likely runs high until the system recalibrates.

Neurologists call a sustained, involuntary contraction that pulls a body part into a posture dystonia, and in withdrawal it travels with tremor, twitches, jerks, and the inner restlessness known as akathisia. No test proves the link between a given jaw and a given taper, and nobody has studied it properly. What follows is what physicians who see withdrawal learn to recognize, and it varies from one patient to the next.

What does the withdrawal pattern look like?

It tends to be on both sides. The chewing muscles ache on both sides and both sides of the neck pull, while TMD from a damaged joint is more often one-sided. Imaging of the joint is normal, and a mouth that will not open fully is being held by muscle rather than by the joint.

It keeps time with the taper. The clenching intensifies in the days after a reduction and eases during a hold, and when that timing repeats over two or three reductions it is the closest thing to a diagnostic test that exists. And, it rarely arrives alone, since tremor, twitching, or restlessness are usually somewhere in the picture.

Patients describe a pull rather than an ache, a force drawing the jaw shut or the head to one side. A pattern we see often is a patient several months into a taper who has had two splints, jaw physical therapy, and joint imaging that showed nothing, with no clonazepam anywhere in the dental chart. The splints protected the teeth, and they were never going to reach the cause.

Why do dentists miss it, and why does neurology call it functional?

A dentist sees jaws, and the TMD framework sorts jaw pain into joint problems and muscle problems. Normal imaging lands you in the muscle category, the muscle category gets a splint and exercises, and the intake form asks about allergies and blood thinners but not about a taper. Unfortunately, many patients leave the benzodiazepine off the form, some because a pill for sleep or anxiety and a sore jaw seem unrelated, and some because of the label that tends to follow it.

Physical dependence on a prescribed medication is not addiction, and a chart that records the medication is doing its job rather than passing judgment. Dependence is the predictable adaptation of a nervous system to a drug it was given for months or years, and it happens to people who took every dose as directed.

Referral to neurology helps only if the neurologist knows withdrawal. One who does not may find a normal MRI, or magnetic resonance imaging, and a normal EEG, or electroencephalogram, and send you back labeled with “functional movement disorder,” the same labeling problem people with benzodiazepine-induced neurological dysfunction, or BIND, meet when BIND is misdiagnosed as functional neurological disorder.

What if it is not withdrawal at all?

A person in withdrawal can also have a bad tooth or a bad heart, so some patterns should be checked rather than waited out. One-sided jaw pain with swelling or fever is a dental or infectious problem until proven otherwise.

A stiff neck with fever and a severe headache needs to be seen the same day. Jaw pain that comes on with exertion, or arrives with chest pressure, shortness of breath, or pain into the arm, can be the heart announcing itself through the jaw.

A neck that twists or eyes that roll upward within days of starting a dopamine-blocking drug such as metoclopramide or an antipsychotic is an acute dystonic reaction, which is treatable. If jaw or neck symptoms come with chest pain, trouble breathing or swallowing, a seizure, sudden weakness, a drooping face, or a change in vision, call 911 or go to the nearest emergency department, and let the withdrawal question wait until you are safe.

The main lever is the pace of the taper.

If the clenching is time-locked to your reductions, the most reliable relief is a slower schedule or a hold at the current dose. The Ashton Manual, in Chapter II, puts it plainly: “If you reach a difficult point, you can stop there for a few weeks if necessary, but you should try to avoid going backwards and increasing your dosage again.” The Maudsley Deprescribing Guidelines take a different view on that last point, allowing a return to the last dose at which you were stable when symptoms are severe, so a step back up is a decision for you and your prescriber to make together, case by case.

Dr. Leeds’ position, and Professor Ashton’s, is that the pace belongs to the patient, worked out with the prescriber rather than imposed by a calendar. That means telling the physician who manages your taper what the jaw is doing and when, since the timing is the evidence, and asking for the hold rather than improvising one with an extra dose, which wears off into rebound and can unsettle a taper that was otherwise holding.

Whatever you do, do not stop the benzodiazepine abruptly. The 2020 benzodiazepine label update from the United States Food and Drug Administration (FDA), the U.S. Food and Drug Administration, warns that stopping suddenly or reducing too fast can bring on severe withdrawal reactions, and it calls for a gradual taper.

What helps while the muscles settle, and what needs care?

Heat and gentle stretching help many patients with the secondary soreness, and low intensity is the point, since deep work can flare a sensitized nervous system. While a bite splint does nothing to the driver, it is worth keeping for the job it was made for, protecting the teeth from grinding.

Muscle relaxants deserve a specific caution. Carisoprodol is broken down to meprobamate, an older sedative with barbiturate-like effects, which acts on the very GABA system your taper is trying to settle and carries a dependence and withdrawal of its own, with tremor, twitching, and in severe cases seizures when it is stopped abruptly.

Cyclobenzaprine adds sedation that blurs the picture, and baclofen and tizanidine have withdrawal syndromes of their own. So, any of these belongs in a conversation with the physician managing the taper rather than in a separate prescription from another office.

Dopamine-blocking drugs are the other trap. Antipsychotics and the nausea drug metoclopramide can cause or worsen dystonia, and with longer use they carry the risk of tardive syndromes, movement disorders that may not go away.

The Ashton Manual, in Chapter III, warns that drugs related to the major tranquilizers, prochlorperazine among them, are sometimes given for nausea during withdrawal, can cause serious motor side effects, and are not recommended as a substitute for benzodiazepines. Dr. Leeds does not treat withdrawal symptoms with antipsychotics, since his relationship to those drugs is helping patients come off of them.

Some patients try magnesium, and some feel it helps. The evidence is limited, and whether to try it is a decision for you and your own physician.

What should I ask for at the workup?

Ask that the benzodiazepine and the taper be written into the dental or TMD chart, with the splint framed as protection during a withdrawal rather than as treatment of a joint disease. Then ask directly whether this could be dystonia from withdrawal rather than TMD of the joint. Even an honest “I am not sure” changes what gets offered next and whether neurology is considered.

If tremor, jerks, or restlessness are present beyond the jaw and neck, ask for a neurology referral with a specific question attached: are these withdrawal-related movement features? A neurologist who knows BIND will frame it that way, and one who does not can still rule out other movement disorders that look similar.

Fortunately, this is a symptom with a direction. With a steadier pace, the jaw and the neck tend to loosen along with the rest of the withdrawal picture, on the nervous system’s timetable rather than the dentist’s, and the physician who manages your taper is the partner who can adjust that pace with you as the muscles report back.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Long COVID and protracted benzodiazepine withdrawal produce symptom profiles that, viewed side by side without reference to their triggering events, are nearly indistinguishable. Fatigue, cognitive dysfunction, post-exertional worsening, orthostatic intolerance, autonomic instability, sleep disturbance, sensory hypersensitivity, and mood changes dominate both pictures. If you have either condition, a clinician evaluating you without an adequate history might arrive at the same differential. The question is whether the shared picture reflects shared mechanisms, whether approaches that help one should be considered for the other, and how to think about patients who have both.

The Clinical Overlap

The list of features shared between long COVID and protracted benzodiazepine withdrawal is lengthy, and if you live with either one you will probably recognize most of it.

Fatigue in both conditions is profound, out of proportion to activity, not relieved by rest, and persistent over months. Cognitive dysfunction shows up as trouble with attention, concentration, and word-finding, slowed processing speed, and short-term memory difficulty. Both populations call it brain fog.

Post-exertional malaise, a reproducible worsening of symptoms after physical or mental exertion, often arrives on a delay of one to three days. It is a defining feature of a subset of long COVID patients and is present in many benzodiazepine withdrawal patients as well.

Orthostatic intolerance, including postural tachycardia syndrome (POTS), orthostatic hypotension, and related autonomic patterns, is common in long COVID, and similar patterns occur in benzodiazepine withdrawal. Wider autonomic dysregulation follows the same script in both: temperature swings, heart rate variability, blood pressure lability, gastrointestinal (GI) dysmotility, and urinary symptoms. Both conditions produce a broad autonomic syndrome rather than isolated features.

Sensory hypersensitivity means intolerance to light, sound, touch, and smell, along with new sensitivity to medications, foods, and environmental stimuli. Sleep is disrupted in both, with unrefreshing sleep, insomnia, and disturbed sleep architecture. Musculoskeletal pain takes the form of widespread myalgia, joint pain, and fibromyalgia-like patterns. Depression, anxiety, and emotional lability appear frequently in both as secondary features of the primary syndrome. Finally, mast cell-associated features, such as new food and drug reactivity, flushing, and hives, occur in subsets of both populations.

A reasonable observer confronted with these feature lists, without the triggering-event information, would struggle to separate the conditions reliably.

Shared Mechanistic Hypotheses

Several mechanisms have been proposed for both conditions. All of them are theories, and none is settled for either condition, let alone for both.

Neuroinflammation, including activation of the brain’s resident immune cells (microglia), is one proposed contributor in long COVID, and the same process is theorized in benzodiazepine-induced neurological dysfunction (BIND). Autonomic dysfunction is another shared category, even though the specific pattern varies from patient to patient. Alteration of the hypothalamic-pituitary-adrenal (HPA) axis, the body’s stress-hormone system, has been suggested in both. Small-vessel and endothelial dysfunction has been proposed in at least some patients with either condition. Mast cell activation is proposed as a contributor in a subset of each. Altered cellular energy metabolism, sometimes called mitochondrial dysfunction, is a further hypothesis that is biologically plausible in both and unproven in either.

The mechanistic overlap does not mean the conditions are the same. Long COVID has a clear viral trigger and is thought to involve persistent viral effects, immune dysregulation from the original infection, and the specific tissue damage that SARS-CoV-2 can produce. Benzodiazepine withdrawal has a clear pharmacologic trigger and is characterized by adaptation of the gamma-aminobutyric acid type A (GABA-A) receptor, autonomic rebound, and the specific cascade that prolonged benzodiazepine exposure produces. The shared downstream picture may reflect a limited number of pathways that the nervous system can follow when it is destabilized by different upstream insults.

The Clinical Importance of Separating Them

Despite the overlap, the distinction has practical consequences, because it decides which lever your own care should pull.

Patients with long COVID and no benzodiazepine exposure do not have the specific receptor-level driver that benzodiazepine withdrawal produces. Taper interventions are not relevant for them. Their trajectory depends on other variables.

Patients with protracted benzodiazepine withdrawal and no COVID infection do not have the post-viral component. Interventions aimed at persistent viral effects, where those become available, are not the central question for them. Their trajectory depends on completing the taper and on autonomic recovery over time.

Patients with both, whether a long COVID patient who was given a benzodiazepine for anxiety or sleep and later faced a taper, or a taper patient who had acute COVID along the way and developed long COVID features, face the combined picture and usually the most difficult management. If you are in this group, the order and pace of any taper is a decision to make with your prescriber, not something to work out from an article.

One caution applies to everyone in this discussion. A shared label is not a reason to skip a workup. Chest pain, fainting, shortness of breath, sudden loss of vision or hearing, a seizure, or a new neurological deficit such as weakness on one side are not features to file under either condition. They need their own evaluation. Call emergency services for chest pain, a seizure, fainting, or trouble breathing.

Approaches That Cross the Boundary

A few approaches used in long COVID have a natural place in protracted benzodiazepine withdrawal as well.

Pacing comes first. Staying within an energy envelope that does not trigger post-exertional worsening is now the usual advice in long COVID and has always been appropriate for benzodiazepine withdrawal patients with the same feature. Both populations tend to be harmed by forced graded exercise and helped by pacing, and if you have post-exertional worsening, this is the single most useful thing to understand about your own activity.

Sleep work is fundamental in both: a consistent wake time, morning light, a dim evening, and structured help with the thoughts and habits that keep insomnia going. Basic medical checks matter too. Checking for deficiencies (vitamin B12, vitamin D, and iron where applicable) and for thyroid problems is worth doing with your doctor, because a correctable problem should not be left hiding under either diagnosis. Neither sleep work nor a normal set of labs is a treatment for the underlying condition. Both are prerequisites for getting better.

Beyond that, some patients and their doctors try other supports for orthostatic symptoms and for mast cell features, from fluids, salt, compression garments, and avoiding known triggers to medications. These are individualized decisions. What one patient tolerates well another does not, and the benzodiazepine withdrawal population is generally more sensitive to any new medication. Anything in this category is decided with your prescriber, who knows your history.

What Not to Do

Two patterns are worth avoiding.

The first is adding a benzodiazepine to a long COVID patient without a clear understanding of the consequences. A patient with long COVID who develops anxiety and insomnia is sometimes prescribed a benzodiazepine that produces short-term relief and a new long-term problem. That new problem is physical dependence, which is not addiction: the nervous system adapts to the drug and objects when it is reduced, whether or not the drug was ever misused. In a population already at risk for persistent neurological symptoms, adding a pharmacologic driver of the same pattern is rarely the right move.

The second is attributing benzodiazepine withdrawal symptoms to long COVID in a patient who happens to have had COVID at some point. A patient with a clear benzodiazepine taper history and a compatible symptom timeline does not have their symptoms explained by a remote infection, even if the infection happened. Misattribution delays the taper-related management that would actually help.

The Underlying Observation

The close similarity between long COVID and protracted benzodiazepine withdrawal is probably telling us something about how the nervous system responds to sustained destabilization. Different upstream insults, viral, pharmacologic, and possibly others, may converge on a limited set of downstream patterns involving neuroinflammation, autonomic dysregulation, and altered sensory processing. Recognizing this does not collapse the two conditions into one. It does suggest that clinicians who work with either population have something to learn from those who work with the other, and that a patient whose picture does not fit neatly into one category may have arrived at the shared state by more than one route.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Foods that were harmless for decades can start causing reactions during a taper.

Have you started reacting to foods that never bothered you before? It is a common question during a benzodiazepine taper and after it. A slice of aged cheese or a glass of wine that was harmless for thirty years now brings flushing, hives, a racing heart, gut cramping, and a wrecked night of sleep.

Unfortunately, the first framework most people reach for is food allergy, and it usually does not fit. These reactions are variable, often delayed, and tied to the ups and downs of the taper and of benzodiazepine-induced neurological dysfunction, or BIND, the lingering syndrome that can follow long benzodiazepine use. The same process can also show up as what looks like a sudden environmental allergy, with no pollen in sight.

Professor C. Heather Ashton noticed the same thing decades ago. The Ashton Manual, in Chapter III, describes an apparent intolerance to certain foods in protracted withdrawal and notes that reliable tests for true food allergy are nearly always negative. So, if it is not allergy, what is it?

True allergy, plain intolerance, and a mast cell reaction are three different things.

A true food allergy runs through immunoglobulin E, or IgE, the antibody that recognizes one specific food protein. The reaction comes within minutes, comes every time you eat that food, and can escalate to a swollen throat.

A plain intolerance is a digestion problem. Lactose intolerance is the familiar example: a missing enzyme, bloating in proportion to the milk, nothing outside the gut.

A mast cell reaction is neither of these. Mast cells are immune cells stationed in the skin, the airways, and the lining of the gut, packed with histamine and other chemical signals. They answer to IgE, but they also answer to nerve signals, stress hormones, heat, and certain foods directly, which is why one reaction can involve skin, heart, nose, and head at once, hours after a meal, on one day and not the next.

The threshold moves. In fact, the same food can pass on Tuesday and fail on Friday, with poor sleep, an infection, a hot day, or a stressful week making the difference. Foods high in histamine, or that prompt its release, are the most reliable offenders: aged cheeses, cured meats, fermented foods, leftovers, canned fish, wine and beer, and often tomatoes, strawberries, citrus, and chocolate.

The clock is the other clue. Reactions that began during the taper, flare after a dose reduction, and rise and fall with the rest of the withdrawal course belong to the withdrawal.

Why would a taper stir up mast cells at all?

The honest answer is that this is a pattern seen in clinic, and the evidence behind it is thin. What is well described is the nervous system in withdrawal, over-excited, with the fight-or-flight side running hot and the threshold for sensation lowered, and mast cells listen to that system, so a nervous system on high alert appears to make them fire more easily. Benzodiazepines are not antihistamines, and the idea that some of them quiet mast cells directly, which withdrawal then unmasks, is an unproven hypothesis.

An analogy that may help, though it is not a perfect one, is a smoke detector with its sensitivity turned up too far. The toast has not changed, but browning a slice now sets off the alarm. Withdrawal has turned up the dial on the detectors, and getting rid of the toaster does not change the setting, which is why cutting out every food that ever set off a reaction rarely helps for long. Fortunately, the setting comes back down with time, and with a taper slow enough that the alarm is not tripped every week.

Which reactions are not withdrawal, and what might your doctor check?

Some reactions should never be filed under withdrawal. Swelling of the lips, tongue, or throat, wheezing, trouble breathing, or fainting after eating is an emergency, and the right response is to call 911, not to wait and see whether it was histamine.

Short of an emergency, a few patterns deserve a workup, as things to discuss rather than a protocol to demand. A reaction that is fast, reproducible, and tied to one food every time behaves like a true IgE allergy, which a blood test for specific IgE or skin prick testing can confirm or rule out. Weight loss, blood in the stool, persistent vomiting, or anemia point to a gut disease of its own, and the blood test for celiac disease only works while gluten is still in your diet, so it belongs before any elimination diet.

Fixed brownish spots that swell into hives when rubbed, flushing episodes with fainting, or an unexplained anaphylactic reaction raise the question of mastocytosis, a rare disease of the mast cells themselves, screened with a baseline blood tryptase level. A fuller evaluation for mast cell activation syndrome, or MCAS, adds a tryptase drawn during a flare and urine tests for histamine breakdown products, and the companion piece on MCAS and BIND explains why the criteria are contested.

While none of these is common in a taper, the cost of missing one is high enough to ask.

Is a low-histamine diet worth a try?

For many patients a short trial is reasonable, and a permanent one is not. Some patients find that a few weeks of fresh, unaged, unfermented food, with a written diary of meals and reactions, tells them whether histamine is part of their problem. If it helps, foods come back one at a time. If it does not help, you learned that cheaply.

A common pattern runs the other way. A patient reacts to Friday pizza a few months into a taper and drops it, then drops tomatoes, then cheese, then bread, and arrives a year later with a list of forty foods, a diet of rice and boiled chicken, and reactions that are no better. The diet became the identity, and the nervous system driving the reactions was never addressed.

While the food list matters, the Ashton Manual’s advice in Chapter III still stands: a normal healthy diet without food fads, and no strict exclusion diet, which the Manual calls usually inadvisable. The companion article on the low-histamine diet covers how to run a trial and, more to the point, how to end one.

Which medicines help, and which ones backfire?

When a doctor treats this pattern, the usual tools are the second-generation antihistamines, sometimes with famotidine, sold as Pepcid, and occasionally oral cromolyn, a mast cell stabilizer. How and whether they are used is your doctor’s call with you. One difference matters here: cetirizine, sold as Zyrtec, makes some people drowsy, and a benzodiazepine adds to that, while loratadine, sold as Claritin, and fexofenadine, sold as Allegra, rarely do.

The first-generation antihistamines are a different matter. Diphenhydramine, sold as Benadryl, and hydroxyzine cross into the brain, cause sedation, and can deepen the fog and unsteadiness of BIND, and hydroxyzine’s own label adds a heart rhythm warning. Dr. Leeds generally steers patients away from them for reactions like these.

The other thing that backfires is an extra benzodiazepine dose to quiet a reaction. Of course, it feels sensible, and reaching for one is not a sign of addiction. Physical dependence is not addiction.

Your nervous system adapted to a daily dose over years and is being asked to adapt back, and every extra dose taken to end a flare restarts that process. Nor should anyone stop a benzodiazepine abruptly, which asks that same nervous system to adapt all at once.

What makes food reactivity worse.

Three habits reliably make things worse. The first is the immunoglobulin G, or IgG, food sensitivity panel. IgG is the antibody your immune system makes to any food it has met, a record of exposure rather than a sign of harm, so the report tends to list, with great confidence, the foods you ate last month.

The second is permanent exclusion, which shrinks a diet toward nothing while the moving threshold means most of those foods would have passed in a better week.

The third is the supplement stack. Quercetin, vitamin C, and diamine oxidase, or DAO, capsules are widely sold for histamine problems, and some patients find one of them worth trying, though the evidence for each is thin and what any of them does in the body is not established. Taking five at once guarantees that nobody, including you, can tell which one is doing anything.

Does it go away?

In Dr. Leeds’ experience, food reactivity that began during a taper moves with the rest of the withdrawal picture. It flares after reductions, settles during holds, and eases over the months to years after the taper ends as the nervous system calms down. Yet, some people keep a degree of extra sensitivity for a long time. Most gradually get their foods back.

Professor Ashton wrote in Chapter III that a steady decline in symptoms almost invariably continues after withdrawal, though it can take a long time. The Maudsley Deprescribing Guidelines make a related point, that when reductions bring symptoms you cannot live with, the answer is to hold or slow them rather than push through. A food list that grows after every cut is one way your nervous system tells you the pace is too fast.

So, treat these reactions as a feature of withdrawal rather than a new disease, keep the diet as wide as you can tolerate, and let the taper set its own pace. Time does most of the rest, and you will likely eat that cheese again.

This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.